---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-25-000034"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2025-02-06T23:59:59+00:00"
generated_at: "2026-05-27T02:13:21.620505+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine reports Q4 INGREZZA sales $615M (+23% YoY); 2025 guidance $2.5-2.6B

## Summary
- INGREZZA net product sales $2.3B for FY2024, up 26% YoY; Q4 sales $615M (+23% YoY).
- CRENESSITY (crinecerfont) approved Dec 2024 for classic CAH; initial Q4 sales $2M.
- Non-GAAP diluted EPS Q4 $1.69 vs $1.54 prior year; GAAP EPS $1.00 vs $1.44 (higher stock-based comp).
- 2025 INGREZZA sales guidance $2.5-2.6B; Phase 3 osavampator and NBI-568 starting H1 2025.
- Completed $300M ASR program in Feb 2025, repurchased ~2.3M shares; cash $1.816B.

## SEC filing metadata
- accession: 0000914475-25-000034
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2025-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/0000914475-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447525000034/nbix-20250206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-25-000034
- JSON: https://secwatch.observer/filing/0000914475-25-000034.json
- Plain text: https://secwatch.observer/filing/0000914475-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.